文献速递术前评估与围术期医学疼痛医学

CHRM3 rs2165870多态性与术后恶心呕吐独立相关,联合预防有效

CHRM3 rs2165870 polymorphism is independently associated with postoperative nausea and vomiting, but combined prophylaxis is effective.
PubMed 文献 · Br J Anaesth · 2018-04-04

这项前瞻性对照研究纳入454例择期手术患者,检测CHRM3 rs2165870多态性并随机给予穴位刺激/地塞米松等干预。结果显示该多态性与PONV风险独立相关(GA vs GG RR 1.5,AA vs GG RR 1.6),且不依赖Apfel评分;在低Apfel评分但高遗传风险的AA基因型患者中,联合预防可大幅降低PONV风险。

要点

  • CHRM3 rs2165870多态性与PONV风险独立相关,GA和AA基因型风险高于GG。
  • 该遗传风险独立于Apfel评分,低Apfel评分患者仍可能因基因型高风险发生PONV。
  • 低Apfel评分但高遗传风险的AA基因型患者,联合预防可显著降低PONV风险。

核心结论

  • CHRM3 rs2165870多态性与Apfel评分独立预测PONV易感性。
  • 低Apfel评分但高遗传风险的患者应考虑地塞米松联合穴位刺激预防PONV。

研究设计与样本

  • 前瞻性对照研究,纳入454例择期手术受试者,进行rs2165870基因分型并用log-binomial回归分析关联。
  • 受试者随机接受穴位刺激/地塞米松、穴位刺激/对照、假穴位刺激/地塞米松或假穴位刺激/对照以探究对PONV风险的影响。

主要发现

  • 早期PONV发生于37%的受试者。
  • rs2165870基因型分布为GG 191例、GA 207例、AA 56例。
  • GA vs GG基因型发生PONV的相对风险RR为1.5(95%CI 1.1-1.9;P=0.003),AA vs GG为1.6(95%CI 1.1-2.2;P=0.009),且独立于Apfel评分(每增加1分RR 1.3,95%CI 1.2-1.5;P<0.0001)。
  • 在低Apfel评分的AA基因型携带者中,地塞米松和穴位刺激各自降低PONV风险30%,联合治疗降低86%(P=0.015)。

关键数值与推荐

  • GA vs GG基因型发生PONV的RR 1.5(95%CI 1.1-1.9;P=0.003)。
  • AA vs GG基因型发生PONV的RR 1.6(95%CI 1.1-2.2;P=0.009)。
  • Apfel评分每增加1分的RR 1.3(95%CI 1.2-1.5;P<0.0001)。
  • 低Apfel评分的AA基因型携带者中,地塞米松或穴位刺激单用降低PONV风险30%,联合降低86%(P=0.015)。

临床怎么用

  • 对于低Apfel评分但携带CHRM3 rs2165870 AA基因型的患者,应考虑地塞米松联合穴位刺激以预防PONV。
  • 遗传风险独立于Apfel评分,提示低Apfel评分患者仍可能因基因型高风险而需加强预防。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical risk factors for postoperative nausea and vomiting (PONV) are evaluated with the Apfel score, however patients with low Apfel scores still experience PONV suggesting a genetic predisposition. PONV risk associates with specific M3 muscarinic acetylcholine receptor (CHRM3) rs 2165870 polymorphism. We investigated whether the Apfel score and this genetic variation independently contribute to PONV risk and whether prophylaxis reduces PONV in patients with low Apfel score but at high genetic risk. METHODS: In a prospective, controlled study, 454 subjects undergoing elective surgery were genotyped for rs2165870 and its association with PONV was investigated with log-binomial regression analysis. Subjects were randomised to receive acustimulation/dexamethasone, acustimulation/vehicle, sham acustimulation/dexamethasone, or sham acustimulation/vehicle to investigate their effects on PONV risk. RESULTS: Early PONV occurred in 37% of subjects. The rs2165870 genotype distribution was GG in 191, GA in 207, and AA in 56 subjects. The CHRM3 polymorphism was associated with a relative risk (RR) of 1.5 for GA vs GG [95% confidence interval (CI): 1.1-1.9; P=0.003] and 1.6 for AA vs GG (95% CI: 1.1-2.2; P=0.009) genotypes to develop PONV, and this was independent from the Apfel score (RR per Apfel point: 1.3, 95% CI: 1.2-1.5; P<0.0001). While dexamethasone and acustimulation each reduced the PONV risk by 30% in AA genotype carriers with low Apfel score, combined therapy reduced the risk by 86% (P=0.015). CONCLUSIONS: The CHRM3 polymorphism and the Apfel score independently predict PONV susceptibility. Dexamethasone/acustimulation should be considered in patients with low Apfel score but at high genetic risk. CLINICAL TRIAL REGISTRATION: DRKS00005664.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. Klenke S, de Vries GJ, Schiefer L, et al. CHRM3 rs2165870 polymorphism is independently associated with postoperative nausea and vomiting, but combined prophylaxis is effective. Br J Anaesth. 2018. PMID: 29935595. doi:10.1016/j.bja.2018.02.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。